Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05742061
Other study ID # MS 54-1-2023
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date April 2023
Est. completion date December 2023

Study information

Verified date February 2023
Source Benha University
Contact Arwa S. Amer, MD
Phone 01550465282
Email arwa.amer@fmed.bu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Knee osteoarthritis is the most common type of osteoarthritis in the lower extremity and constitutes 23% of all arthritis cases, about 13% of females and 10% of males aged above 60 years have symptomatic knee OA. Intra-articular corticosteroids (IACs) are a frequently-used treatment regimen for pain relief from symptomatic knee OA as it inhibits inflammation and reduces prostaglandin synthesis. Platelet-rich plasma (PRP) is an autologous blood product containing a high percentage of various growth factors (GFs), such as fibroblast growth factor, epidermal growth factor, vascular endothelial growth factor, transforming growth factor-β and platelet-derived growth factor. The aim of this study is to compare effect of intra-articular injection of platelet rich plasma versus corticosteroid in treatment of primary knee osteoarthritis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 2023
Est. primary completion date October 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Patients 40-70 years of age suffering from knee OA with Kellgren Lawrence grade II or III on standing antero-posterior and lateral knee radiographs. - Patients diagnosed according to ACR classification criteria. Exclusion Criteria: - Systemic diseases as Patients having diabetes mellitus,Cardiovascular diseases or coagulopathies. - Those receiving treatment with anticoagulant , anti_platelet medications or systemic corticosteroid 10 days before injection or recent use of NSAIDs. - Pregnant and breast feeding females. - Patients have hemoglobin values <10 g/dl or platelet values<150,000/ml.

Study Design


Intervention

Drug:
Corticosteroid
The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
Other:
Platelet Rich Plasma
PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Benha University

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of knee pain, stiffness and physical function prior knee injection Assessment through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. The final score for the WOMAC was determined by adding the aggregate scores for pain, stiffness, and function. Scores range from 0 to 96 for the total WOMAC where 0 represents the best health status and 96 the worst possible status. Assessment will be done just before injection
Primary Assessment of knee pain, stiffness and physical function 2 weeks after injection Assessment through WOMAC score 2 weeks after injection
Primary Assessment of knee pain, stiffness and physical function 6 weeks after injection Assessment through WOMAC score 6 weeks after injection
Primary Assessment of knee pain, stiffness and physical function 12 weeks after injection Assessment through WOMAC score 12 weeks after injection
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06232018 - A Comparison of 2-octyl Cyanoacrylate Skin Adhesive and Polyester Mesh for Wound Closure in Total Knee Arthroplasty, A Randomized Controlled Study N/A
Recruiting NCT02200107 - Integrated Treatment Program for Osteoarthritis of the Knee N/A
Recruiting NCT05783154 - Effect of Mesenchymal Stem Cells in Primary Knee Osteoarthritis Phase 2/Phase 3
Completed NCT02833545 - Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis Phase 4
Recruiting NCT01569230 - Efficacy and Safety Study of Individualized and Standardized Acupuncture Treatment for Knee Osteoarthritis N/A
Completed NCT02314715 - Neuromuscular Control in Knee Osteoarthritis N/A
Active, not recruiting NCT03548792 - Comparison of an Old Versus a New Total Knee Replacement N/A
Completed NCT02285725 - Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid N/A
Completed NCT02544802 - Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee Phase 1
Completed NCT02919020 - Efficacy of Proprioceptive Neuromuscular Facilitation in Older Women With Gonarthrosis N/A
Completed NCT02050438 - How Total Knee Prosthesis Dessigns Influence in Quality of Live N/A
Completed NCT01492660 - Echogenic Versus Stimulating Needle and Catheter for Sciatic Blocks Phase 3
Completed NCT01934218 - Gel-One Treatment in Knee Osteoarthritis N/A
Completed NCT04324931 - Effect of Biomechanical Correction in Medial Tibiofemoral Joint Osteoarthritis N/A